At 10-year post-diagnosis, stage III/IV (vs 0), intermediate- and high- (vs low-) grade BC were associated with a higher PAA of 4.48 (<i>p</i><0.001), 1.26 (<i>p</i>=0.03), and 1.95 (<i>p</i>=0.001), respectively; triple-negative (vs hormone receptor+/HER2-) BC was associated with a lower PAA (ΔPAA=-1.96, <i>p</i>=0.004). This evidence concerns the gene ERBB2 and breast cancer.